Literature DB >> 11078566

Cognitive and behavioral profile of fragile X boys: correlations to molecular data.

M Backes1, B Genç, J Schreck, W Doerfler, G Lehmkuhl, A von Gontard.   

Abstract

Fragile X syndrome (FXS) is the most common form of inherited mental retardation after Down syndrome. The expansion of a CGG repeat, located in the 5'-untranslated region (5'-UTR) of the FMR1 (fragile X mental retardation) gene, leads to the hypermethylation of the repeat and the upstream CpG island. Methylation is associated with transcriptional silencing of the FMR1 gene. The lack of FMR1 protein is believed to be responsible for the typical physical and mental characteristics of the syndrome. To analyze the specific phenotype of that syndrome as well as possible associations between the phenotype and the genotype, we examined a group of 49 fragile X boys and a control group of 16 patients with tuberous sclerosis. To determine the cognitive and behavioral phenotype, the Kaufman Assessment Battery for Children (K-ABC), the Child Behavior Checklist (4/18), and a structured psychiatric interview (Kinder DIPS) were used. The genotype was analyzed by the Southern blot method. The phenotype of boys with FXS is characterized by a specific cognitive profile with strengths in acquired knowledge and in simultaneous processing. The psychiatric comorbidity is high and ADHD (attention deficit hyperactivity disorder), oppositional defiant disorder, enuresis, and encopresis predominate. In a group of 24 fragile X boys, no significant correlations between the specific aspects of the phenotype and the genotype were found. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078566

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  27 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

2.  Cognitive aspects of Fragile X syndrome.

Authors:  Lillie B Huddleston; Jeannie Visootsak; Stephanie L Sherman
Journal:  Wiley Interdiscip Rev Cogn Sci       Date:  2014-05-29

3.  Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome.

Authors:  Ovsanna T Leyfer; Janet Woodruff-Borden; Bonita P Klein-Tasman; Johanna S Fricke; Carolyn B Mervis
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-09-05       Impact factor: 3.568

Review 4.  Attention deficits, Attention-Deficit Hyperactivity Disorder, and intellectual disabilities.

Authors:  Curtis K Deutsch; William V Dube; William J McIlvane
Journal:  Dev Disabil Res Rev       Date:  2008

Review 5.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Detailed assessment of incontinence in boys with fragile-X-syndrome in a home setting.

Authors:  Justine Niemczyk; Alexander von Gontard; Monika Equit; Katharina Bauer; Teresa Naumann; C Wagner; Leopold Curfs
Journal:  Eur J Pediatr       Date:  2016-08-27       Impact factor: 3.183

Review 7.  Co-existing disorders in ADHD -- implications for diagnosis and intervention.

Authors:  Christopher Gillberg; I Carina Gillberg; Peder Rasmussen; Björn Kadesjö; Henrik Söderström; Mania Råstam; Mato Johnson; Aribert Rothenberger; Lena Niklasson
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

8.  Anxiety disorders in children with williams syndrome, their mothers, and their siblings: implications for the etiology of anxiety disorders.

Authors:  Ovsanna Leyfer; Janet Woodruff-Borden; Carolyn B Mervis
Journal:  J Neurodev Disord       Date:  2009-03       Impact factor: 4.025

9.  The prevalence and phenomenology of repetitive behavior in genetic syndromes.

Authors:  Joanna Moss; Chris Oliver; Kate Arron; Cheryl Burbidge; Katy Berg
Journal:  J Autism Dev Disord       Date:  2008-11-27

10.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.

Authors:  Bridget M Dolan; Sergio G Duron; David A Campbell; Benedikt Vollrath; B S Shankaranarayana Rao; Hui-Yeon Ko; Gregory G Lin; Arvind Govindarajan; Se-Young Choi; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.